169 related articles for article (PubMed ID: 15467209)
1. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation.
Khan MZ; Rausl D; Zanoski R; Zidar S; Mikulcić JH; Krizmanić L; Eskinja M; Mildner B; Knezević Z
Biol Pharm Bull; 2004 Oct; 27(10):1630-5. PubMed ID: 15467209
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
3. Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine, Post-Bariatric Surgery.
Porat D; Dukhno O; Vainer E; Cvijić S; Dahan A
Mol Pharm; 2022 Aug; 19(8):2922-2936. PubMed ID: 35759355
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceutical classification of desloratadine - not all drugs are classified the easy way.
Berginc K; Sibinovska N; Žakelj S; Trontelj J; Legen I
Acta Pharm; 2020 Jun; 70(2):131-144. PubMed ID: 31955139
[TBL] [Abstract][Full Text] [Related]
5. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
6. Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes.
Szabados-Nacsa A; Sipos P; Martinek T; Mándity I; Blazsó G; Balogh Á; Szabó-Révész P; Aigner Z
J Pharm Biomed Anal; 2011 May; 55(2):294-300. PubMed ID: 21316895
[TBL] [Abstract][Full Text] [Related]
7. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
[TBL] [Abstract][Full Text] [Related]
8. The Evaluation of Valsartan Biopharmaceutics Properties.
de Castro LML; de Souza J; Caldeira TG; de Carvalho Mapa B; Soares AFM; Pegorelli BG; Della Croce CC; Barcellos NMS
Curr Drug Res Rev; 2020; 12(1):52-62. PubMed ID: 31820707
[TBL] [Abstract][Full Text] [Related]
9. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.
Charoo NA; Cristofoletti R; Dressman JB
J Pharm Pharmacol; 2015 Aug; 67(8):1156-69. PubMed ID: 25828546
[TBL] [Abstract][Full Text] [Related]
10. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.
Franek F; Jarlfors A; Larsen F; Holm P; Steffansen B
Eur J Pharm Sci; 2015 Sep; 77():303-13. PubMed ID: 26091569
[TBL] [Abstract][Full Text] [Related]
11. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership.
Yang Y; Faustino PJ; Volpe DA; Ellison CD; Lyon RC; Yu LX
Mol Pharm; 2007; 4(4):608-14. PubMed ID: 17637014
[TBL] [Abstract][Full Text] [Related]
13. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
Wei H; Löbenberg R
Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
15. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
16. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
17. Intestinal permeability study of minoxidil: assessment of minoxidil as a high permeability reference drug for biopharmaceutics classification.
Ozawa M; Tsume Y; Zur M; Dahan A; Amidon GL
Mol Pharm; 2015 Jan; 12(1):204-11. PubMed ID: 25423288
[TBL] [Abstract][Full Text] [Related]
18. Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola
Hens B; Bermejo M; Cristofoletti R; Amidon GE; Amidon GL
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32570975
[TBL] [Abstract][Full Text] [Related]
19. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
20. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
